Alentis Therapeutics is a clinical-stage company pioneering anti-CLDN1 antibody-drug conjugates (ADCs) and antibodies to treat CLDN1+ tumors and fibrotic disease. Its lead programs, ALE.P02 (tubulin inhibitor payload) and ALE.P03 (topoisomerase I inhibitor payload), are first-in-class ADCs designed to target a unique CLDN1 epitope on cancer cells. The company plans Phase 1/2 clinical studies for ALE.P02 and ALE.P03, with an IND for ALE.P02 recently cleared by the FDA. ALE.P02’s Phase 1/2 trial is expected to commence in Q1 2025, and a first-in-human trial for ALE.P03 is planned in 2025. Alentis was founded on research from Prof. Thomas Baumert’s lab and maintains headquarters in Basel, Switzerland with R&D in Strasbourg and clinical operations in the U.S. The company says its CLDN1 programs aim to deliver potent anti-cancer activity with reduced toxicity compared with traditional chemotherapies. Alentis Therapeutics is a clinical-stage biotech focused on developing breakthrough treatments that target Claudin‑1 (CLDN1) for organ fibrosis and CLDN1‑positive solid tumors. Its lead investigational products are ALE.F02 and ALE.C04, with ALE.F02 nearing completion of its MAD study and ALE.C04 being developed for CLDN1+ oncology populations including T‑cell excluded cancers. Alentis has built a CLDN1 platform to engineer antibody‑drug conjugates (ADCs) and bi‑specific antibodies and is advancing that platform alongside its clinical programs. The company plans to use new funding to support a Phase II program for ALE.F02, a Phase I program for ALE.C04, continue recruitment for organ fibrosis trials, and further develop its ADC and bi‑specific programs. Alentis was founded in 2019 and is headquartered in Basel, Switzerland, with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Financially, the company has raised a $105 million Series C following a $67 million Series B in June 2021 to accelerate clinical development and platform advancement. Alentis Therapeutics is developing first‑in‑class, Claudin‑1‑targeting monoclonal antibodies (lead candidates ALE.F02 and ALE.C04) to treat liver, kidney and other organ fibrosis and fibrosis-driven hepatobiliary cancers. Preclinical studies showed ALE.F02 can modulate non-junctional Claudin‑1 to prevent and possibly reverse fibrotic tissue growth, and safety studies in non-human primates supported translatability to patients. The company uses a patient-derived drug and target discovery platform and has early discovery programs exploring Claudin‑1 inhibition in kidney and lung fibrosis. Alentis plans to use the Series B proceeds primarily to fund proof‑of‑concept clinical trials in advanced liver and kidney fibrosis and to support ongoing drug discovery programs and oncology indications. The company expects to initiate its first clinical trial in Q4 2021. Alentis was founded in 2019 based on research from Prof. Thomas Baumert's laboratory, is headquartered in Basel with an R&D subsidiary in Strasbourg, and recently completed a $67M (CHF60M) Series B. Alentis Therapeutics is developing novel therapeutics focused on advanced liver disease and hepatocellular carcinoma. The company is advancing a humanized monoclonal antibody against a target implicated in liver fibrosis and HCC. Its research is powered by a proprietary drug discovery platform based on a prognostic liver disease signature, which the company says holds promise for discovering additional drug candidates. Alentis was founded on research from the laboratory of Prof. Thomas Baumert at the University of Strasbourg and collaborators including Prof. Yujin Hoshida at UT Southwestern. The company is headquartered in Basel and maintains a subsidiary in Strasbourg and a branch in Germany. It recently completed a Series A financing and announced a new CEO, Markus L.E. Ewert.

Total raised

$365M

Funding rounds

4

Latest round

Series D

Latest activity

Nov 2024